{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:29:07Z","timestamp":1794047347846,"version":"4.8.0"},"reference-count":35,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"3","license":[{"start":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T00:00:00Z","timestamp":1582761600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Four cycles of rituximab plus CHOP chemotherapy is as effective as 6 cycles in low-risk diffuse large B-cell lymphoma (DLBCL). Here we report a post-hoc analysis of a prospective clinical trial in patients with HIV-associated DLBCL and high-grade lymphoma treated with 4\u20136 cycles of EPOCH plus rituximab based a response-adapted treatment strategy. 106 evaluable patients with HIV-associated DLBCL or high-grade CD20-positive non-Hodgkin's lymphoma were randomized to receive rituximab (375 mg\/m2) given either concurrently prior to each infusional EPOCH cycle, or sequentially (weekly for 6 weeks) following completion of EPOCH. EPOCH consisted of a 96-hour IV infusion of etoposide, doxorubicin, and vincristine plus oral prednisone followed by IV bolus cyclophosphamide every 21 days for 4 to 6 cycles. Patients received 2 additional cycles of therapy after documentation of a complete response (CR) by computerized tomography after cycles 2 and 4. 64 of 106 evaluable patients (60%, 95% CI 50%, 70%) had a CR in both treatment arms. The 2-year event-free survival (EFS) rates were similar in the 24 patients with CR who received 4 or fewer EPOCH cycles (78%, 95% confidence intervals [55%, 90%]) due to achieving a CR after 2 cycles, compared with those who received 5-6 cycles of EPOCH (85%, 95% CI 70%, 93%) because a CR was first documented after cycle 4. A response-adapted strategy may permit a shorter treatment duration without compromising therapeutic efficacy in patients with HIV-associated lymphoma treated with EPOCH plus rituximab, which merits further evaluation in additional prospective trials. Clinical Trials.gov identifier NCT00049036<\/jats:p>","DOI":"10.3324\/haematol.2019.243386","type":"journal-article","created":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T11:24:31Z","timestamp":1582802671000},"page":"730-735","source":"Crossref","is-referenced-by-count":15,"title":["Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in HIV-associated, B-cell non-Hodgkin's lymphoma"],"prefix":"10.3324","volume":"106","author":[{"family":"Joseph A. Sparano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Jeannette Y. Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Lawrence D. Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Juan Carlos Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Richard F. Ambinder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"William Wachsman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"David Aboulafia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Ariela Noy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"David H. Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Lee Ratner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Ethel Cesarman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Amy Chadburn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Ronald Mitsuyasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2020,2,27]]},"reference":[{"key":"22218","doi-asserted-by":"crossref","unstructured":"Tilly H, Gomes da Silva M, Vitolo U. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015; 26(Suppl 5):116-125.","DOI":"10.1093\/annonc\/mdv304"},{"key":"22219","doi-asserted-by":"crossref","unstructured":"Zelenetz AD, Abramson JS, Advani RH. NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. J Natl Compr Canc Netw. 2010; 8(3):288-334.","DOI":"10.6004\/jnccn.2010.0021"},{"key":"22220","doi-asserted-by":"crossref","unstructured":"Wasterlid T, Biccler JL, Brown PN. Six cycles of R-CHOP-21 are not inferior to eight cycles for treatment of diffuse large Bcell lymphoma: a Nordic Lymphoma Group population-based study. Ann Oncol. 2018; 29(8):1882-1883.","DOI":"10.1093\/annonc\/mdy184"},{"key":"22221","doi-asserted-by":"crossref","unstructured":"Poeschel V, Held G, Ziepert M. Excellent outcome of young patients (18-60 years) with favourable-prognosis diffuse large B-cell lymphoma treated with 4 cycles CHOP plus 6 applications of rituximab: results of the 592 patients of the FLYER trial of the DSHNHL\/GLA. Blood. 2018; 132(Suppl 1):781.","DOI":"10.1182\/blood-2018-99-112403"},{"key":"22222","doi-asserted-by":"crossref","unstructured":"Sparano JA, Weller E, Nazeer T. Phase 2 trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with poor-prognosis, intermediate-grade non- Hodgkin lymphoma: an Eastern Cooperative Oncology Group trial (E3493). Blood. 2002; 100(5):1634-1640.","DOI":"10.1182\/blood.V100.5.1634.h81702001634_1634_1640"},{"key":"22223","doi-asserted-by":"crossref","unstructured":"Sparano JA, Wiernik PH, Leaf A, Dutcher JP. Infusional cyclophosphamide, doxorubicin, and etoposide in relapsed and resistant non- Hodgkin's lymphoma: evidence for a schedule- dependent effect favoring infusional administration of chemotherapy. J Clin Oncol. 1993; 11(6):1071-1079.","DOI":"10.1200\/JCO.1993.11.6.1071"},{"key":"22224","doi-asserted-by":"crossref","unstructured":"Wilson WH, Bryant G, Bates S. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J Clin Oncol. 1993; 11(8):1573-1582.","DOI":"10.1200\/JCO.1993.11.8.1573"},{"key":"22225","doi-asserted-by":"crossref","unstructured":"Wilson WH, Grossbard ML, Pittaluga S. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood. 2002; 99(8):2685-2693.","DOI":"10.1182\/blood.V99.8.2685"},{"key":"22226","doi-asserted-by":"crossref","unstructured":"Little RF, Pittaluga S, Grant N. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood. 2003; 101(12):4653-4659.","DOI":"10.1182\/blood-2002-11-3589"},{"key":"22227","doi-asserted-by":"crossref","unstructured":"Sparano JA, Wiernik PH, Hu X. Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide plus didanosine and filgrastim in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma. J Clin Oncol. 1996; 14(11):3026-3035.","DOI":"10.1200\/JCO.1996.14.11.3026"},{"key":"22228","doi-asserted-by":"crossref","unstructured":"Sparano JA, Lee S, Chen MG. Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIVassociated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group trial (E1494). J Clin Oncol. 2004; 22(8):1491-1500.","DOI":"10.1200\/JCO.2004.08.195"},{"key":"22229","doi-asserted-by":"crossref","unstructured":"Spina M, Jaeger U, Sparano JA. Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials. Blood. 2005; 105(5):1891-1897.","DOI":"10.1182\/blood-2004-08-3300"},{"key":"22230","doi-asserted-by":"crossref","unstructured":"Sparano JA. HIV-associated lymphoma: the evidence for treating aggressively but with caution. Curr Opin Oncol. 2007; 19(5):458-463.","DOI":"10.1097\/CCO.0b013e3282c8c835"},{"key":"22231","doi-asserted-by":"crossref","unstructured":"Sparano JA, Lee JY, Kaplan LD. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood. 2010; 115(15):3008-3016.","DOI":"10.1182\/blood-2009-08-231613"},{"key":"22232","doi-asserted-by":"crossref","unstructured":"Kaplan LD, Lee JY, Ambinder RF. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood. 2005; 106(5):1538-1543.","DOI":"10.1182\/blood-2005-04-1437"},{"key":"22233","doi-asserted-by":"crossref","unstructured":"Cheson BD, Horning SJ, Coiffier B. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999; 17(4)","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"22234","doi-asserted-by":"crossref","unstructured":"Barta SK, Joshi J, Mounier N. Central nervous system involvement in AIDS-related lymphomas. Br J Haematol. 2016; 173(6):857-866.","DOI":"10.1111\/bjh.13998"},{"key":"22235","unstructured":"Ngongondo M, Kang M, Umbleja T. Early progression and immune reconstitution inflammatory syndrome during treatment of mild-to-moderate Kaposi sarcoma in low-resource settings: incidence, longterm outcomes and effects of early chemotherapy. 2019."},{"key":"22236","doi-asserted-by":"crossref","unstructured":"Dunleavy K, Pittaluga S, Shovlin M. Low-intensity therapy in adults with Burkitt's lymphoma. N Engl J Med. 2013; 369(20):1915-1925.","DOI":"10.1056\/NEJMoa1308392"},{"key":"22237","doi-asserted-by":"crossref","unstructured":"Dunleavy K, Noy A, Abramson JS. Risk-adapted therapy in adults with Burkitt lymphoma: preliminary report of a multicenter prospective phase II study of DAEPOCH- R. Blood. 2015; 126(23):342-342.","DOI":"10.1182\/blood.V126.23.342.342"},{"key":"22238","doi-asserted-by":"crossref","unstructured":"Barta SK, Xue X, Wang D. Treatment factors affecting outcomes in HIV- associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients. Blood. 2013; 122(19):3251-3262.","DOI":"10.1182\/blood-2013-04-498964"},{"key":"22239","doi-asserted-by":"crossref","unstructured":"Chadburn A, Chiu A, Lee JY. Immunophenotypic analysis of AIDS- related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034. J Clin Oncol. 2009; 27(30):5039-5048.","DOI":"10.1200\/JCO.2008.20.5450"},{"key":"22240","doi-asserted-by":"crossref","unstructured":"Dunleavy K, Little RF, Pittaluga S. The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood. 2010; 115(15):3017-3024.","DOI":"10.1182\/blood-2009-11-253039"},{"key":"22241","doi-asserted-by":"crossref","unstructured":"Schmitz R, Wright GW, Huang DW. Genetics and pathogenesis of diffuse large Bcell lymphoma. N Engl J Med. 2018; 378(15):1396-1407.","DOI":"10.1056\/NEJMoa1801445"},{"key":"22242","doi-asserted-by":"crossref","unstructured":"Mikhaeel NG, Timothy AR, O'Doherty MJ, Hain S, Maisey MN. 18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin's lymphoma -comparison with CT. Leuk Lymphoma. 2000; 39(5-6):543-553.","DOI":"10.3109\/10428190009113384"},{"key":"22243","doi-asserted-by":"crossref","unstructured":"Spaepen K, Stroobants S, Dupont P. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non- Hodgkin's lymphoma. Ann Oncol. 2002; 13(9):1356-1363.","DOI":"10.1093\/annonc\/mdf256"},{"key":"22244","doi-asserted-by":"crossref","unstructured":"Haioun C, Itti E, Rahmouni A. [18F]fluoro- 2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood. 2005; 106(4):1376-1381.","DOI":"10.1182\/blood-2005-01-0272"},{"key":"22245","doi-asserted-by":"crossref","unstructured":"Dupuis J, Itti E, Rahmouni A. Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria. Ann Oncol. 2009; 20(3):503-507.","DOI":"10.1093\/annonc\/mdn671"},{"key":"22246","doi-asserted-by":"crossref","unstructured":"Carr R, Fanti S, Paez D. Prospective international cohort study demonstrates inability of interim PET to predict treatment failure in diffuse large B-cell lymphoma. J Nucl Med. 2014; 55(12):1936-1944.","DOI":"10.2967\/jnumed.114.145326"},{"key":"22247","doi-asserted-by":"crossref","unstructured":"Dabaja BS, Vanderplas AM, Crosby-Thompson AL. Radiation for diffuse large B-cell lymphoma in the rituximab era: analysis of the National Comprehensive Cancer Network lymphoma outcomes project. Cancer. 2015; 121(7):1032-1039.","DOI":"10.1002\/cncr.29113"},{"key":"22248","doi-asserted-by":"crossref","unstructured":"Mamot C, Klingbiel D, Hitz F. Final results of a prospective evaluation of the predictive value of interim positron emission tomography in patients with diffuse large B-cell lymphoma treated with RCHOP- 14 (SAKK 38\/07). J Clin Oncol. 2015; 33(23):2523-2529.","DOI":"10.1200\/JCO.2014.58.9846"},{"key":"22249","doi-asserted-by":"crossref","unstructured":"Swinnen LJ, Li H, Quon A. Responseadapted therapy for aggressive non- Hodgkin's lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404). Br J Haematol. 2015; 170(1):56-65.","DOI":"10.1111\/bjh.13389"},{"key":"22250","doi-asserted-by":"crossref","unstructured":"Duhrsen U, Muller S, Hertenstein B. Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): a multicenter, randomized phase III trial. J Clin Oncol. 2018; 36(20):2024-2034.","DOI":"10.1200\/JCO.2017.76.8093"},{"key":"22251","doi-asserted-by":"crossref","unstructured":"Casasnovas RO, Ysebaert L, Thieblemont C. FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study. Blood. 2017; 130(11):1315-1326.","DOI":"10.1182\/blood-2017-02-766691"},{"key":"22252","doi-asserted-by":"crossref","unstructured":"Mhlanga JC, Durand D, Tsai HL. Differentiation of HIV-associated lymphoma from HIV-associated reactive adenopathy using quantitative FDG PET and symmetry. Eur J Med Mol Imaging. 2014; 41(4):596-604.","DOI":"10.1007\/s00259-013-2671-9"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/9673\/70640","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/9673\/70641","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/9673\/70640","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T09:56:19Z","timestamp":1794045379000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/9673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,27]]},"references-count":35,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2019.243386","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2,27]]}}}